Overview

A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

Status:
Active, not recruiting

Trial end date:
2022-12-28

Target enrollment:

Participant gender:

Summary

This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Fulvestrant